The US market for Hemostats and Sealants accelerated in Q418 driven by growth in fibrin sealants and thrombin hemostats, overcoming slow growth during the first half of the year.
The US market for Hemostats and Sealants accelerated with +9.3% YoY growth in Q418, continuing to build on its +7.9% YoY in Q318, with fibrin sealants and thrombin hemostats driving the increase. The US market grew +6.1% in FY18, overcoming slow growth during the first half of the year.
As reported in SmartTRAK Financial Dashboard, every manufacturer in the Hemostats and Sealants market, except Pfizer and CryoLife, experienced revenue growth in Q418. Leading the way was Baxter with +33.1% YoY growth as it made progress with its integration of the Mallinckrodt portfolio. Ethicon and Becton Dickinson (BD) both posted solid gains, with +8.7% YoY and +6.6% YoY growth, respectively...
Among the many topics covered in the Q418/FY18 Hemostats and Sealants Market Recap are:
- Ethicon Continues to Lead Hemostats and Sealants
- Thrombins Build On Their Growth
- Fibrin Leads the Way In Sealants
- Q418 events in the US Hemostats and Sealants Market:
The US Hemostats and Sealants market increased +9.3% YoY and up +29.3% QoQ from Q318. This increase reflects seasonality in hemostat and sealant revenues as surgeries are scheduled in the fourth quarter once deductibles are exceeded. All competitors except Pfizer and CryoLife posted gains for the quarter. These gains also allowed the market to achieve good overall growth in FY18, finishing up +6.1% YoY on revenues of...
*This article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
